Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Amortizatization of Intangibles: 2022-2025

Historic Amortizatization of Intangibles for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $1.6 million.

  • Axsome Therapeutics' Amortizatization of Intangibles rose 0.06% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 0.27%. This contributed to the annual value of $6.4 million for FY2024, which is 0.27% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Amortizatization of Intangibles is $1.6 million, which was up 1.13% from $1.6 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Amortizatization of Intangibles high stood at $1.6 million for Q3 2022, and its period low was $275,000 during Q1 2022.
  • In the last 3 years, Axsome Therapeutics' Amortizatization of Intangibles had a median value of $1.6 million in 2023 and averaged $1.6 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first skyrocketed by 481.82% in 2023, then decreased by 1.07% in 2025.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Amortizatization of Intangibles stood at $1.6 million in 2022, then remained steady at $1.6 million in 2023, then remained steady at $1.6 million in 2024, then grew by 0.06% to $1.6 million in 2025.
  • Its Amortizatization of Intangibles stands at $1.6 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.6 million for Q1 2025.